BackgroundRetinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to explore the prognostic significance of RXRG in breast cancer.MethodsPrimary breast cancer tissue microarrays (n = 923) were immuno-stained for RXRG protein and correlated with clinicopathological features, and patient outcome.ResultsNuclear RXRG expression was significantly associated with smaller tumour size (p = 0.036), lower grade(p p = 0.016), lower Nottingham Prognostic Index (p = 0.04) and longer breast cancer-specific survival (p p = 0.002). RXRG expression showed positive association with oestrogen receptor (ER)-related biomarkers: GATA3, FOXA1, STAT3 and MED7 (allp RXRGexpression was associated with improved patients’ outcome (p = 0.025). In ER-positive tumours, high expression of RXRG was associated with better patient outcome regardless of adjuvant systemic therapy. ER signalling pathway was the top predicted master regulator of RXRG protein expression (p = 0.005).ConclusionThis study provides evidence for the prognostic value of RXRG in breast cancer particularly the ER-positive tumours.
